Co-Authors
This is a "connection" page, showing publications co-authored by Mark Rubinstein and John Wrangle.
Connection Strength
3.437
-
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers. J Immunol. 2022 03 15; 208(6):1362-1370.
Score: 0.861
-
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
Score: 0.657
-
IL-2 and Beyond in Cancer Immunotherapy. J Interferon Cytokine Res. 2018 02; 38(2):45-68.
Score: 0.649
-
Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer. Mol Ther. 2017 09 06; 25(9):1995-1996.
Score: 0.629
-
Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res. 2018 06 01; 78(11):3067-3074.
Score: 0.164
-
Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis. Cancer Immunol Immunother. 2017 Jun; 66(6):737-751.
Score: 0.153
-
Harnessing the IL-7/IL-7Ra axis to improve tumor immunotherapy. Oncoimmunology. 2016 May; 5(5):e1122865.
Score: 0.141
-
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100426.
Score: 0.052
-
Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. iScience. 2021 Jun 25; 24(6):102489.
Score: 0.051
-
The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. Cancer. 2018 04 15; 124(8):1650-1659.
Score: 0.040
-
?-catenin and PI3Kd inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. JCI Insight. 2017 Apr 20; 2(8).
Score: 0.038